Telomir-1 Shows Promise in Reducing PSA Levels in Human Prostate Cancer Cells

Telomir Pharmaceuticals reported new data showing that Telomir-1 significantly reduces PSA levels in human prostate cancer cells. PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response. Telomir-1 lowered PSA levels in a dose-related manner, indicating its potential in treating prostate cancer. The findings are consistent with previous data from a mouse model implanted with aggressive human prostate cancer cells.